证券代码：300199 证券简称：翰宇药业 深圳翰宇药业股份有限公司 2025 年度向特定对象发行 A 股股票 方案论证分析报告 二〇二五年九月 1 深圳翰宇药业股份有限公司（以下简称"翰宇药业"或"公司"）是深圳证 券交易所创业板上市公司。为满足公司业务发展的资金需求，增加公司资本实力， 提升盈利能力，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）和《上市公司证券发行注册管理办 法》（以下简称"《注册管理办法》"）等有关法律法规和规范性文件的规定，公司 拟实施 2025 年度向特定对象发行 A 股股票（以下简称"本次发行"），本次发 行募集资金总额不超过 96,800.00 万元（含本数），在扣除发行费用后拟全部用于 以下项目： | 单位：万元 | | --- | | 序号 | 项目名称 | 项目投资总额 | 拟使用募集资金金 | | --- | --- | --- | --- | | | | | 额 | | 1 | 多肽药物产线及绿色智能化扩建项目 | 54,948.00 | 49,500.00 | | 2 | 多肽片段扩产建设项目 | 4,5 ...

证券代码：300199 证券简称：翰宇药业 公告编号：2025-041 一、本次发行摊薄即期回报对公司主要财务指标的影响 （一）财务测算主要假设和说明 以下假设仅为测算本次向特定对象发行 A 股股票摊薄即期回报对公司主要 财务指标的影响，并不代表公司对2025年度和2026年度经营情况及趋势的判断， 亦不构成盈利预测。投资者不应据此进行投资决策，投资者据此进行投资决策造 成损失的，公司不承担任何赔偿责任。 深圳翰宇药业股份有限公司 1、假设公司所处的宏观经济环境、产业政策、行业发展状况、产品市场情 况等方面没有发生重大变化； 关于 2025 年度向特定对象发行 A 股股票摊薄即期回报 2、假设本次发行于 2026 年 6 月 30 日完成，该完成时间仅用于计算本次以 特定对象发行摊薄即期回报对主要财务指标的影响，最终以经中国证监会同意注 册后实际发行完成的时间为准； 的风险提示及填补措施和相关主体承诺的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳翰宇药业股份有限公司（以下简称"公司"）于 2025 年 9 月 25 日召开 第六届董事会第七次会议 ...

二〇二五年九月 1 一、本次募集资金的使用计划 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）向特定对象发 行股票拟募集资金总额不超过人民币 96,800.00 万元（含本数），扣除相关发行费 用后的募集资金净额将全部用于以下项目： 证券代码：300199 证券简称：翰宇药业 深圳翰宇药业股份有限公司 2025 年度向特定对象发行 A 股股票 募集资金使用可行性分析报告 单位：万元 | 序号 | 项目名称 | 项目投资总额 | 拟使用募集资金 | | --- | --- | --- | --- | | | | | 金额 | | 1 | 多肽药物产线及绿色智能化扩建项目 | 54,948.00 | 49,500.00 | | 2 | 多肽片段扩产建设项目 | 4,580.00 | 4,000.00 | | 3 | 研发实验室升级项目 | 5,775.00 | 5,500.00 | | 4 | 司美格鲁肽研发项目 | 13,280.00 | 9,800.00 | | 4.1 | 司美格鲁肽国内上市注射剂（降糖适应症） | 5,700.00 | 2,500.00 | | 4.2 | 司美格鲁肽美国上市口 ...

证券代码：300199 证券简称：翰宇药业 公告编号：2025-043 披露的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳翰宇药业股份有限公司于 2025 年 9 月 25 日召开了第六届董事会第七次 会议和第六届监事会第四次会议，会议审议通过了关于 2025 年度向特定对象发 行 A 股股票的相关议案。《深圳翰宇药业股份有限公司 2025 年度向特定对象发 行 A 股股票预案》（以下简称"预案"）及相关公告已于同日在中国证监会指 定的创业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）上披露，敬请 广大投资者注意查阅。 该预案披露事项不代表审核机关对于本次向特定对象发行股票相关事项的 实质性判断、确认或批准，预案所述本次发行股票相关事项的生效和完成尚需获 得深圳证券交易所审核通过和中国证券监督管理委员会的同意注册，敬请广大投 资者注意投资风险。 特此公告。 深圳翰宇药业股份有限公司董事会 2025 年 9 月 26 日 深圳翰宇药业股份有限公司 关于 2025 年度向特定对象发行股票预案 ...

证券代码：300199 证券简称：翰宇药业 深圳翰宇药业股份有限公司 2025 年度向特定对象发行 A 股股票 预案 二〇二五年九月 1 深圳翰宇药业股份有限公司 2025 年度向特定对象发行 A 股股票预案 公司声明 1、公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不存 在虚假记载、误导性陈述或重大遗漏，对预案的真实性、准确性、完整性承担个 别和连带的法律责任。 2、本次发行预案（以下简称"本预案"）按照《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司证券发行注册管理办法》等法律、法规及规范 性文件的要求编制。 3、本次向特定对象发行 A 股股票完成后，公司经营与收益的变化由公司自 行负责；因本次向特定对象发行 A 股股票引致的投资风险，由投资者自行负责。 4、本预案是公司董事会对本次向特定对象发行 A 股股票的说明，任何与之 相反的声明均属不实陈述。 5、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或 其他专业顾问。 6、本预案所述事项并不代表审批机关对于本次向特定对象发行 A 股股票相 关事项的实质性判断、确认或批准，本预案所述本次发行相关事项的生效和完成 尚待 ...

Core Viewpoint - The company announced the approval of a plan to issue A-shares to specific investors during a board meeting scheduled for September 25, 2025, pending regulatory approvals [1] Group 1 - The company will hold a board and supervisory board meeting on September 25, 2025, to review the proposal for the issuance of A-shares [1] - The relevant proposal and announcement have been disclosed on the Giant Tide Information Network [1] - The issuance of shares is subject to approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission [1]

深圳翰宇药业股份有限公司第六届董事会 第二次独立董事专门会议审核意见 根据《中华人民共和国公司法》（以下简称《公司法》）《中华人民共和国 证券法》（以下简称《证券法》）《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相 关法律、法规及规范性文件的规定以及《公司章程》《独立董事工作细则》的有 关规定，我们作为公司的独立董事，基于独立判断的立场，本着实事求是的原则， 召开了第六届董事会第二次独立董事专门会议。 本次会议应出席独立董事 3 人，实际出席独立董事 3 人，独立董事认真审阅 了议案内容，在保证所获得的资料真实、准确、完整的基础上，本着勤勉尽责的 态度，基于独立客观的原则并发表审核意见如下： 一、《关于公司符合向特定对象发行 A 股股票条件的议案》的审核意见 经审核，我们认为：根据《公司法》《证券法》《上市公司证券发行注册管 理办法》（以下简称《注册管理办法》）等相关法律、法规及规范性文件的规定， 对照上市公司向特定对象发行股票（以下简称"本次发行"）相关资格、条件和 要求，经对公司的实际情况进行逐项自查，我们认为公司符合上述相关法律、法 ...

Group 1 - The cell immunotherapy sector experienced a decline of 2.75%, ranking among the top losers in the concept sector, with ST Zhongzhu hitting the daily limit down [1] - Major stocks within the cell immunotherapy sector that saw significant declines include Zhaoyan New Drug, Jimin Health, and Boteng Co., with respective drops of 6.04%, 5.45%, and 5.34% [1][2] - The sector faced a net outflow of 1.61 billion yuan from main funds, with 48 stocks experiencing outflows, and six stocks seeing outflows exceeding 100 million yuan, led by Hengrui Medicine with a net outflow of 293 million yuan [2] Group 2 - The top gainers in today's concept sectors included the SMIC concept with a rise of 1.22% and the National Big Fund holding with an increase of 1.08% [2] - The main inflows were observed in stocks such as Betta Pharmaceuticals, Chutian Technology, and Rongchang Bio, with net inflows of 35.97 million yuan, 21.30 million yuan, and 14.08 million yuan respectively [4] - The overall market sentiment reflected a mixed performance across various sectors, with notable declines in the Huawei Pangu and MLOps concepts, down 3.69% and 3.31% respectively [2]

Core Insights - The report highlights the recent performance of major stock indices, indicating a slight decline across the board, with the Shanghai Composite Index closing at 3820.09, down by 0.30% [3] - It emphasizes the ongoing market dynamics, including sector performance, with tourism, coal, and engineering machinery showing gains, while sectors like multi-finance and automotive services faced significant declines [8] Macro News Summary - The People's Bank of China, along with financial regulatory bodies, will hold a press conference to discuss achievements in the financial sector during the 14th Five-Year Plan period [5] - Shanghai has released a notification to optimize and adjust personal housing property tax pilot policies [5] - The Ministry of Industry and Information Technology has issued a plan to stabilize growth in the light industry, aiming to support the industry's recovery [5] Industry Updates - The Ministry of Industry and Information Technology plans to accelerate the research and industrialization of advanced technologies such as solid-state batteries and sodium-ion batteries, with related stocks including CATL and Xianlead Intelligent [6] - Energy storage installations have increased twentyfold over the past five years, with a focus on safety technology in the second half of the year, involving stocks like Sungrow Power and EVE Energy [6] - The 11th batch of drug procurement has introduced the concept of "anti-involution," shifting away from a "low-price only" approach, impacting stocks like Hengrui Medicine and Hanyu Pharmaceutical [6] Company Focus - Allwinner Technology has developed several chip products based on the RISC-V architecture, with its chips being used in Xiaomi's bionic quadruped robot [7] - Youloka's lightweight guided products have platform adaptability for applications in quadruped robots and drones [7] - Jinghua New Materials plans to invest approximately 1 billion yuan to establish a new adhesive material project with an annual production capacity of 480 million square meters [7] - Changdian Technology's testing services cover various storage chip products, with storage business revenue increasing by over 150% year-on-year in the first half of the year [7] Market Review and Outlook - The market experienced a slight decline last week, with the total trading volume in the Shanghai and Shenzhen markets at 2.32 trillion yuan, a decrease of 811.3 billion yuan from the previous trading day [8] - The report notes a rotation in market focus, with high positions being adjusted and funds shifting towards dividend stocks, suggesting caution against chasing high-flying stocks [8] - The technical analysis indicates that after reaching a new high of 3899 points, the Shanghai Composite Index is undergoing a short-term adjustment, with expectations of continued upward movement [8] - The report suggests that with ongoing favorable market liquidity, investors should focus on valuation recovery opportunities post-interest rate cuts, as well as sectors related to "anti-involution" and domestic consumption [8]

Group 1 - On September 19, Hanyu Pharmaceutical experienced a decline of 2.74% with a trading volume of 1.232 billion yuan [1] - The financing data on the same day showed a financing purchase amount of 120 million yuan and a financing repayment of 159 million yuan, resulting in a net financing outflow of 38.83 million yuan [1] - As of September 19, the total balance of margin trading for Hanyu Pharmaceutical was 1.473 billion yuan, accounting for 6.91% of its circulating market value, which is above the 80th percentile of the past year [1] Group 2 - As of June 30, the number of shareholders for Hanyu Pharmaceutical reached 63,000, an increase of 9.95% compared to the previous period [2] - The company reported a revenue of 549 million yuan for the first half of 2025, representing a year-on-year growth of 114.86%, and a net profit attributable to shareholders of 145 million yuan, a significant increase of 1504.30% [2] - Since its A-share listing, Hanyu Pharmaceutical has distributed a total of 417 million yuan in dividends, with no dividends paid in the last three years [2]